Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows us to maintain our leadership position in the space. • Best-in-class LNP + next generation ligand conjugate technologies • First and only FDA-approved siRNA-LNP utilizes Genevant technology • Nucleic acid payload design expertise • Several hundred patents worldwide • LNP technology evaluated in more than a dozen clinical programs, representing hundreds of subjects and patients • An established leader in delivery to the liver, now focusing capabilities on other tissues and cell types • Experienced team with deep technical expertise and a track record of innovation and creative corporate partnering
| Website | http://www.genevant.com |
| Revenue | $17 million |
| Employees | 56 (40 on RocketReach) |
| Founded | 2017 |
| Phone | +1 857-259-4127 |
| Technologies |
JavaScript
,
HTML
,
PHP
+17 more
(view full list)
|
| Industry | Biotechnology, Biopharma, RNA, Rare Disease, Health Care, Drug Development, Science and Engineering, Biologics, Life Science, RNAi, Medical, Srna, Pharmaceutical, Mrna, Oligonucleotides, IND, Research, LNP delivery, Lipid nano-particles, Extrahepatic, Drug Delivery, Formulations |
| Competitors | Siemens Healthineers, Pfizer, Amgen, Moderna Therapeutics, CureVac, Galileo International L.L.C, 维亚生物科技(上海)有限公司, RaNA Therapeutics, NantKwest, eTheRNA +40 more (view full list) |
Looking for a particular Genevant Sciences employee's phone or email?
The Genevant Sciences annual revenue was $17 million in 2026.
James Heyes is the CEO of Genevant Sciences.
40 people are employed at Genevant Sciences.